<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03209180</url>
  </required_header>
  <id_info>
    <org_study_id>CVDSR</org_study_id>
    <nct_id>NCT03209180</nct_id>
  </id_info>
  <brief_title>Immediate Release Versus Slow Release Carvedilol in Heart Failure</brief_title>
  <acronym>SLOW-HF</acronym>
  <official_title>Assessment of Clinical Effect and Treatment Quality of Rapid Release Carvedilol Versus SLOW Release Carvedilol-SR in HEART FAILURE Patient (SLOW-HF): A Prospective Randomized, Open-label, Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of clinical effect and treatment quality of immediate release carvedilol (IR)
      versus slow release carvedilol (SR) in patients with HFrEF
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The SLOW-HF trial is a phase 4, randomized, open label, multicenter study to evaluate the
      therapeutic efficacy of carvedilol-SR compared to carvedilol-IR in patients with heart
      failure with reduced ejection fraction. Patients with stable HFrEF will be randomly assigned
      (1:1) to carvedilol SR group (160 patients) and carvedilol IR group (160 patients).

      After randomization, patients will be followed for 6 months. The primary endpoint is the
      change in NT-proBNP level from baseline to the study end. The secondary endpoints include the
      frequency of NT-proBNP increment &gt;10% from baseline, composite of all-cause mortality and
      readmission, mortality rate, readmission rate, changes in blood pressure, quality of life,
      and drug compliance.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 27, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>PROBE and NON-INFERIORITY DESIGN for Slow Release CarVeDilol-SR to Rapid Release Carvedilol-IR</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NT-proBNP</measure>
    <time_frame>6 months</time_frame>
    <description>Change of NT-proBNP from baseline to 6 months after randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause Death</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in all-cause deaths between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in hospitalization for heart failure between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in blood pressure change between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in dyspnea measured with visual analogue scale between the groups during clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug compliance</measure>
    <time_frame>6 months</time_frame>
    <description>Differences in drug compliance measured with 'pill-count' between the groups during clinical follow-up</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Heart Failure With Reduced Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Carvedilol IR (Immediate Release)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carvedilol IR 3.125mg, 6.25mg, 12.5mg, 25mg twice daily p.o. for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CarVeDilol-SR (Slow Release)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CarVeDilol-SR 8mg, 16mg, 32mg, 64mg once daily p.o. for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CarVeDilol-SR (Slow Release)</intervention_name>
    <description>patients will receive slow-release carvedilol (SR) once daily</description>
    <arm_group_label>CarVeDilol-SR (Slow Release)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol IR (Immediate Release)</intervention_name>
    <description>patients will receive immediate release carvedilol (IR) twice daily</description>
    <arm_group_label>Carvedilol IR (Immediate Release)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. At least or more than 20-years-old male and female

          2. Confirmed left ventricular ejection fraction ≤40% by echocardiography within
             pre-analytical 6 months

          3. NT-proBNP level ≥ 125 pg/ml or BNP level ≥ 35 pg/ml within pre-analytical 3 months

          4. Clinically stable patient without evidence of congestion or extracellular fluid
             retention; those could be candidate of β-blockers

          5. Patients providing written informed consent

        Exclusion Criteria:

          1. Systolic blood pressure at sitting position &lt; 90mmHg or resting heart rate &lt; 50 /min
             at screening

          2. Patient has a contraindication to β-blockers

          3. Patient who are expected to take another β-blocker after randomization

          4. Cardiovascular diseases

               -  Ischemic heart disease (unstable angina, myocardial infarction) within 1 month

               -  Hypertrophic cardiomyopathy

               -  Cor pulmonale

               -  Hemodynamically significant stenosis of aorta, aortic valve, or mitral valve

               -  any acute myocardial infarction with complication

          5. Severe cerebrovascular accident (for example, ischemic stroke or cerebral hemorrhage)
             pre-analytical within 6 months

          6. Glottis edema, allergic rhinitis, respiratory diseases with bronchospasm such as
             asthma and chronic obstructive lung disease

          7. Peripheral vascular disease (for example, Raynaud syndrome, intermittent claudication)

          8. Patients who need vasopressor due to prominent volume retention/overload

          9. Moderate to Severe retinopathy (for example, retinal hemorrhage, visual disturbance,
             retinal microaneurysm within 6 months)

         10. Impaired renal function (Serum creatinine ≥ 2.5 mg/dL) or hepatic function (AST or ALT
             ≥ 3 x ULM)

         11. Patients in clinical status that can significantly influence on absorption,
             distribution, metabolism, and secretion of drugs for clinical trial

               -  history of major gastrointestinal surgery, such as gastrectomy or gastric bypass
                  surgery

               -  inflammatory bowel disease within 12 months

               -  current gastric ulcer, pancreatic function abnormality including pancreatitis,
                  gastrointestinal/rectal bleeding which demand treatment

               -  current urologic stenosis or obstruction which demand treatment

         12. Confirmed or suspected drug/alcohol abuse within 6 months

         13. Pregnant or lactating women, suspected pregnant women or lactating women

         14. Chronic inflammatory diseases which demand anti-inflammatory treatment

         15. Hypersensitivity to carvedilol

         16. Malignant disease including lymphoma and leukemia within 5 years

         17. Patients who were prescribed other medication for any clinical trials pre-analytical
             within 28 days

         18. Patients who are predicted to have prolonged hospital days due to other medical
             problems other than chronic heart failure (for example, femur neck fracture)

         19. Patients who are considered as inappropriate to participate in the clinical trial by
             testers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sejong Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Bucheon</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suk-keun Hong, MD</last_name>
      <phone>82-10-8947-5309</phone>
      <email>hongsk11@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Gangdong</state>
        <zip>05355</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dae-gyun Park, MD</last_name>
      <phone>82-2-2224-2379</phone>
      <email>dgpark@hallym.or.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Univ. Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Guro</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eung-joo Kim, MD,PhD</last_name>
      <phone>82-8-2626-3022</phone>
      <email>withnoel@empas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Il-won</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eun-Seok Jeon, MD,PhD</last_name>
      <phone>82-2-3410-3448</phone>
      <email>esjeon1107@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Jungnang</state>
        <zip>02053</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Yeon Kim, MD</last_name>
      <phone>82-2-2276-7095</phone>
      <email>ks7688@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea Univ. Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seongbuk</state>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun-jun Hong, MD,PhD</last_name>
      <phone>82-2-920-5445</phone>
      <email>psyche94@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae-Joong Kim, MD,PhD</last_name>
      <phone>82-2-3010-3154</phone>
      <email>jjkim@amc.seoul.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou Univ. Medical Center</name>
      <address>
        <city>Suwon-si</city>
        <state>Yeong-tong</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun-han Shin, MD,PhD</last_name>
      <phone>82-31-219-5710</phone>
      <email>shinjh@ajou.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Ju Choi, MD, PhD</last_name>
      <phone>82-31-787-7007</phone>
      <email>djchoi@snubh.org</email>
    </contact>
    <contact_backup>
      <last_name>Jin Joo Park, MD</last_name>
      <phone>82-31-787</phone>
      <phone_ext>7074</phone_ext>
      <email>jinjooparkmd@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seok-Min Kang, MD,PhD</last_name>
      <phone>82-2-2273-3339</phone>
      <email>smkang@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Metropolitan Government Seoul National University Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>07061</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung-a Kim</last_name>
      <phone>82-2-870-2213</phone>
      <email>kma@brmh.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hae-Young Lee, MD,Ph D</last_name>
      <phone>82-2-2072-4875</phone>
      <email>hylee612@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <zip>26426</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byung-Su Yoo, MD,PhD</last_name>
      <phone>82-33-741-0908</phone>
      <email>yubs@yonsei.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2017</study_first_submitted>
  <study_first_submitted_qc>July 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 6, 2017</study_first_posted>
  <last_update_submitted>July 3, 2017</last_update_submitted>
  <last_update_submitted_qc>July 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Professor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>HFrEF</keyword>
  <keyword>Carvedilol</keyword>
  <keyword>Slow Release</keyword>
  <keyword>NT-proBNP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

